Efficacy and Cost-Effectiveness of MDM2 Fluorescence In Situ Hybridization (FISH) in Morphologically Atypical Spermatic Cord Lipomas.
Noor Z., Hegazy S., Naous R.
Laboratory Study with a reported sample of 43, published in Cureus (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cureus (2025)
- Country
- United States
- Reported sample size
- 43
- Source database
- PubMed
- PMID
- 40799874
- DOI
- 10.7759/cureus.87852
Abstract (original English)
Spermatic cord lipomas originate from preperitoneal adipose tissue within the internal spermatic fascia and are found in 20%-70% of all inguinal hernia repairs. Morphologically, spermatic cord lipomas may harbor some atypical features, including increased stromal cellularity with thickened fibrous bands, occasional lipoblasts, and stromal nuclear atypia or hyperchromasia, raising concern for well-differentiated liposarcoma (WDLS) versus reactive-type atypia. Fluorescence in situ hybridization (FISH) for MDM2 amplification would be the gold standard test in such cases. The aim of this study was to evaluate the efficacy and cost-effectiveness of MDM2 FISH in diagnostically discrimination morphologically atypical spermatic cord lipoma cases at our institution. All cases with "specimen type" labeled as "spermatic cord lipoma" between 2018 and 2023 were retrospectively retrieved from our institutional archives. Cases were included in the study group if they had MDM2 FISH performed. Cases with a prior history of spermatic cord well-differentiated liposarcoma with positive MDM2 amplification were excluded. MDM2 amplification status and corresponding final diagnosis were recorded. Three hundred twenty specimens labelled as spermatic cord lipoma were retrieved from our archives. Forty-three out of 320 had MDM2 FISH performed. All 43 cases demonstrated atypical features and appeared morp
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.